Compugen Ltd. · NASDAQ:CGEN
Compugen — Investor Presentation (May 2023)
7 slides from Compugen's investor presentation, May 15, 2023
Slide 1: COM503: Differentiated approach to harness cytokine biology for cancer therapeutics
CO M 5 0 3 - D i f fe re nt i ate d a p p ro a c h to h a r n e s s c y to k i n e b i o l o g y fo r c a n c e r t h e ra p e u t i c s
Slide 2: Cytokines' powerful potential limited by therapeutic window
C y to k i n e s p o we r f u l p o te nt i a l l i m i te d b y t h e ra p e u t i c w i n d o w • Short half life • Short half life • Short half-life • Short half-life • Pleiotropy • Systemic • Bound to IL-18BP • Vascular leak inflammation inhibiting activity syndrome • Myelotoxicity in TME • Card
Slide 3: COM503: Compugen identified potential dominant immunosuppression mechanism and antibody therapeutic
CO M 5 0 3 : C o m p u ge n i d e nt i f i e d p o te nt i a l d o m i n a nt i m m u n o s u p p re s s i o n m e c h a n i s m a n d a nt i b o d y t h e ra p e u t i c Interleukin-18 binding protein, an endogenous inhibitor of interleukin -18 DAMPs Myeloid/ Inflammasome IL-18 immune stimulatory c
Slide 4: COM503: advantages of a differentiated approach
CO M 5 0 3 : a d va nta ge s o f a d i f fe re nt i ate d a p p ro a c h COM503 anti-IL-18 binding protein Engineered IL-18 Conventional cytokine approaches limited success to Novel antibody approach date, no FDA approval in last 30 years Novelty Anti-IL-18BP releases endogenous IL-18 in the TME IL-
Slide 5: Fully human, high affinity antibody restores human TIL and NK cell activity
CO M 5 0 3 f u l l y h u m a n , h i g h a f f i n i t y a nt i - I L 1 8 B P a nt i b o d y re sto re s h u m a n T I L a n d N K c e l l a c t i v i t y COM503 restores TILs activity COM503 restores NK cell activity 4000 400 IFN (pg/ml) 300 3000 IFN [pg/ml] 200 2000 100 1000 0 Tumor cell line 0
Slide 6: Anti-IL-18BP Ab demonstrates monotherapy activity across murine syngeneic tumor models
A nt i - I L - 1 8 B P a nt i b o d y d e m o n st rate s m o n o t h e ra p y a c t i v i t y a c ro s s m u r i n e sy n ge n e i c t u m o r m o d e l s aIL-18BP Ab inhibits tumor aIL-18BP Ab inhibits tumor aIL-18BP Ab inhibits tumor growth in E0771 orthotopic growth in MC38ova mouse growth in B1
Slide 7: Anti-IL-18BP Ab modulates tumor microenvironment without affecting the periphery in murine tumor model
A nt i - I L - 1 8 B P a nt i b o d y m o d u l ate s t u m o r m i c ro e nv i ro n m e nt w i t h o u t a f fe c t i n g t h e p e r i p h e r y i n m u r i n e t u m o r m o d e l Monotherapy with anti-IL-18BP Ab immune-modulated tumor microenvironment in MC38ova model Immune modulation restricte